Previsão

O preço-alvo médio dos analistas é € 23,77 (+82,29%). A mediana é € 25,53 (+95,78%).

Comprar	9
Manter	1
Vender	1

Notícias Ir para o feed de notícias

Dynavax president exercises 114,000 options and sells shares amid Sanofi acquisition

David Novack, President & COO of Dynavax, exercised 114,000 stock options and immediately sold the resulting shares for about $1.8 million, leaving him with 63,344 shares (≈0.05% of outstanding). The options exercised comprised 20,000 at $6.80 and 94,000 at $10.47, producing net proceeds of roughly $680,000 after costs. The transaction occurred as Dynavax shares traded near the $15.50 per-share acquisition price agreed with Sanofi. » Mais em finance.yahoo.com
Dynavax to be acquired by Sanofi for $2.2 billion; shares jump 38%

Dynavax agreed to be acquired by Sanofi for $2.2 billion, with an offer of $15.50 per share representing about a 39% premium to the Dec. 23 close. The deal brings Dynavax’s adult hepatitis B vaccine Heplisav-B and shingles candidate Z-1018 into Sanofi’s portfolio. Dynavax said Sanofi’s global scale will help maximize the vaccines’ commercial and development potential. » Mais em finance.yahoo.com
Dynavax secures exclusive license for Vaxart oral COVID-19 vaccine for $25m

Dynavax has entered a worldwide exclusive license agreement with Vaxart to develop and commercialize Vaxart’s oral COVID-19 vaccine, paying an upfront $25m plus a $5m equity stake. Vaxart remains responsible for development until completion of the ongoing Phase‑2b study; Dynavax may assume further development at the end of 2026 for an additional $50m. Milestone payments to Vaxart could total up to $620m, plus royalties on future sales; the Phase‑2b trial with about 5,400 participants is funded under Project NextGen. Dynavax is described as financially well positioned but is currently not profitable; the company also announced a new $100m share buyback program. » Mais em de.investing.com

Dividendos históricos Dividendos

Todos os indicadores de dividendos Todos os indicadores

Em 2022, Dynavax Technologies Co. já distribuiu € 0,26 em dividendos. A última distribuição ocorreu em março de 2022.

Dados financeiros da empresa

No último trimestre, Dynavax Technologies Co. registou receitas de € 80,85 mi e um ganho líquido de € 22,95 mi

(EUR)	setembro de 2025	YoY
Receitas	80,85 mi	-
Ganho bruto	68,57 mi	-
Ganho líquido	22,95 mi	-
EBITDA	27,17 mi	-

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 1,6 bi
Número de ações	117,42 mi
Máximo/mínimo de 52 semanas	€ 13,85 - € 8,10
Dividendos	Não
Beta	0,93
PER (PE Ratio)	-40,79
PEG (PEG Ratio)	0,08
P/VC (PB Ratio)	3,40
P/V (PS Ratio)	7,04

Perfil da empresa

Dynavax Technologies Corporation, ein biopharmazeutisches Unternehmen, konzentriert sich auf die Entwicklung und Vermarktung neuartiger Impfstoffe in den Vereinigten Staaten. Das Unternehmen vermarktet HEPLISAV-B, einen Hepatitis-B-Impfstoff zur Vorbeugung von Infektionen, die durch alle bekannten Subtypen des Hepatitis-B-Virus im Alter von 18 Jahren und älter in den Vereinigten Staaten und Europa verursacht werden. Das Unternehmen produziert und vertreibt auch das Adjuvans CpG 1018, das in HEPLISAV-B verwendet wird. Dynavax Technologies Corporation hat eine Kooperationsvereinbarung mit Valneva Scotland Limited, eine Vereinbarung mit Serum Institute of India Pvt. Ltd. und eine Unterlizenzvereinbarung mit Merck, Sharp & Dohme Corp. Das Unternehmen war früher unter dem Namen Double Helix Corporation bekannt und änderte im September 1996 seinen Namen in Dynavax Technologies Corporation. Die Dynavax Technologies Corporation wurde 1996 gegründet und hat ihren Hauptsitz in Emeryville, Kalifornien.

Nome	Dynavax Technologies Co.
CEO	Ryan Spencer
Sede	EmeryVille, ca EUA
Site	dynavax.com
Setor	Materiais básicos
Indústria	Produtos químicos
Entrada em bolsa	19/02/2004
Colaboradores	405